Clinical Trial Update: Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial [Phase 3]

View source ↗

Summary

This Phase III trial update evaluates a biweekly regimen of eribulin versus a standard regimen for locally recurrent or metastatic HER2-negative breast cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: Ma Fei，MD | Conditions: Breast Cancer Metastatic | Phase 3 | Status: ENROLLING_BY_INVITATION